Navigation Links
Simcere Pharmaceutical Group to Announce First Quarter 2013 Financial Results on Thursday, May 9, 2013
Date:4/26/2013

NANJING, China, April 26, 2013 /PRNewswire/ -- Simcere Pharmaceutical Group (NYSE: SCR), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced that it will report its unaudited financial results for the first quarter ended March 31, 2013 on Thursday, May 9, 2013, before the market opens in the United States. Simcere's management will host an earnings conference call on the same day at 8 a.m. ET (Thursday, May 9, at 8 p.m. Beijing/Hong Kong time).

To access the conference call, please dial:International toll: 

+65.6723.9381United States toll-free: 

+1.866.519.4004United States toll: 

+1.718.354.1231China Domestic toll: 

800.819.0121 China Domestic mobile toll: 

400.620.8038 Hong Kong toll: 

+852.2475.0994Please ask to be connected to Q1 2013 Simcere Pharmaceutical Group Earnings Conference Call and provide the following passcode: 58031483.

Simcere will also broadcast a live audio webcast of the conference call. The broadcast will be available by visiting the "Investor Relations" section of the company's web site at www.simcere.com.

Following the earnings conference call, an archive of the call will be available by dialing:United States toll-free:

+1. 855.452.5696United States toll:

+1. 646.254.3697The passcode for replay participants is 58031483. The telephone replay also will be archived on the "Investor Relations" section of the company's website for seven days following the earnings announcement.

About Simcere Pharmaceutical GroupSimcere Pharmaceutical Group (NYSE: SCR, Simcere) is a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, cardiovascular disease, infectious diseases and pain. For more information about Simcere Pharmaceutical Group, please visit www.simcere.com.Investor and Media Contacts: Email: ir@simcere.com In Nanjing:Jie Liu D'EliaVice PresidentSimcere Pharmaceutical GroupTel: 86-25-8556-6666*8857In the United States:Cindy Zheng

Brunswick Group

Tel: 1-212-333-3810In Beijing: Yue YuBrunswick GroupTel: 86-10-5960-8 

 

 


'/>"/>
SOURCE Simcere Pharmaceutical Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Simcere Pharmaceutical Group Announces its Special Committees Engagement of Financial Advisor
2. Simcere Pharmaceutical Group Announces Issuance of GMP Certificate to Simcere Vaxtec
3. Simcere Pharmaceutical Group Announces its Special Committees Engagement of Legal Counsel
4. Simcere Pharmaceutical Group Announces Receipt of "Going Private" Proposal
5. Simcere Pharmaceutical Group Reports Preliminary Unaudited Fourth Quarter And Full Year 2012 Results
6. Simcere Pharmaceutical Group to Announce Fourth Quarter and Fiscal Year 2012 Financial Results on Thursday, March 7, 2013
7. Simcere Pharmaceutical Group Announces Sale of Equity Interest in Shanghai Celgen
8. Simcere Pharmaceutical Group Reports Preliminary Unaudited Third Quarter 2012 Results
9. Simcere Pharmaceutical Group to Announce Third Quarter 2012 Financial Results on Thursday, November 15, 2012
10. Simcere Pharmaceutical Group Announces Appointment of New Chief Executive Officer
11. Simcere Pharmaceutical Group Reports Preliminary Unaudited Second Quarter 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... PARIS , May 25,2016 ... with the near-infrared Cellvizio platform for urological and ... MKEA, OTCQX: MKEAY) inventor of Cellvizio®, the multidisciplinary ... important regulatory milestone in the US with the ... Food and Drug Administration (FDA). This new FDA ...
(Date:5/25/2016)... and GERMANTOWN, Maryland , May 25, 2016 ... ; Frankfurt Prime Standard: QIA) today announced that the company ... Diagnostics GmbH to develop and commercialize predictive assays in oncology. ... as a marker to predict effectiveness of anthracycline treatment in ... "We are pleased to partner with Therawis, which developed the ...
(Date:5/25/2016)... May 25, 2016 According to ... Development, Growth and Demand Forecast to 2022 - Industry ... and Others)" published by P&S Market Research, the global ... in 2015, and it is expected to grow at ... the insulin pump segment is expected to witness the ...
Breaking Medicine Technology:
(Date:5/26/2016)... ... May 26, 2016 , ... W.S. Badger Co. ... been honored with a 2016 When Work Works Award for its use of effective ... the national When Work Works project administered by the Families and Work Institute (FWI) ...
(Date:5/26/2016)... ... May 26, 2016 , ... Intalere, the healthcare ... suppliers for its inaugural Member Conference at the Paris Hotel in Las Vegas, ... operational health of America’s healthcare providers. , The conference was highlighted by the ...
(Date:5/26/2016)... , ... May 26, 2016 , ... Connor Sports, ... basketball as a partner for the Tamika Catchings Legacy Tour that will ... industry leader in hardwood basketball surfaces in all forms and levels of the game, ...
(Date:5/26/2016)... ... ... The Woodlands at John Knox Village , Florida’s first Life Plan ... and healing, celebrated its grand opening, today. The Woodlands at John Knox Village is ... Staff. , “This is an incredibly fulfilling time for John Knox Village as we ...
(Date:5/26/2016)... ... May 26, 2016 , ... There are nearly 14.5 million people living ... survivors worldwide. On Sunday, June 5, 2016, communities around the world will gather to ... , National Cancer Survivors Day® is an annual worldwide Celebration of Life that ...
Breaking Medicine News(10 mins):